Valneva SE (VALN) is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. Headquartered in Saint-Herblain (France), Valneva centralizes all its activities in one place, with integrated research laboratories, manufacturing and commercial functions. With over two decades of experience in vaccine development, it is dedicated to improve the quality of life by empowering everyone to live healthily, without fear of infectious diseases.
Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® for the prevention of Japanese encephalitis, a flu-like syndrome that can cause paralysis, seizures, and death; and DUKORAL® for cholera and, in some countries, prevention of diarrhea caused by ETEC. In addition, Valneva has various vaccines in development, including candidates for Lyme disease, chikungunya, Zika and the SARS-CoV-2 virus. Furthermore, Valneva has a unique end-to-end capability to develop, manufacture and commercialize vaccines, providing a distinguishing competitive advantage.
Valneva’s Lyme disease vaccine candidate, VLA15, is the only active vaccine program in clinical development against Lyme disease, a severe and growing threat to public health. The vaccine is expected to raise awareness about this ubiquitous disease and serve as a preventive measure for people at high risk.
Another key project is their collaboration with UK government for the development of VLA2001. This could possibly be the first inactivated SARS-CoV-2 vaccine developed in Europe. As the world combats the COVID-19 pandemic, Valneva continues to use its expertise in vaccine development and manufacturing to help tackle this global public health crisis.
Valneva operates through broad alliances with some of the largest pharmaceutical companies, including a license agreement with Chemo-Sero-Therapeutic Research Institute (Kaketsuken) for IXIARO/JESPECT and a marketing and distribution agreement with PaxVax for the distribution of DUKORAL and VIVOTIF outside Europe and North America.
With the commitment towards global health and a unique business model that focuses on diseases overlooked by major manufacturers, Valneva is leading the way in creating solutions for those who need it the most. It combines the entrepreneurial spirit of a biotech firm with the industry know-how of a big pharma company, making them a standout in the world of vaccine development.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Research analysts are updating their forecasts for Valneva's Q3 earnings, with HC Wainwright raising its EPS forecast to a loss of $0.18 per share. The company reported a Q2 loss of $0.40 per share, missing consensus estimates, and its revenue also fell short. Analyst sentiment for Valneva remains mixed, resulting in a consensus "Hold" rating and an average price target of $11.98.
Valneva SE (VALN) published its Q2 2026 earnings call presentation on August 14, 2026. The company reported an EPS of -$0.40, missing estimates by $0.32, and revenue of $40.28M, a 28.66% year-over-year decrease, missing estimates by $2.98M. This article provides access to the slide deck presented during the earnings call.
Valneva SE (VALN) stock surged by 26.02% following TD Cowen's initiation of coverage with a Buy rating and a $12 price target. The bullish sentiment is driven by Valneva’s diversified vaccine portfolio and its de-risked Lyme vaccine candidate, LB6V, which is seen as a long-term revenue driver. This analyst endorsement aligns with an existing consensus around a $12.12 price target, reinforcing a positive outlook for the biotech stock among traders.
The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the Lyme disease vaccine candidate developed by Pfizer and Valneva. This validation follows favorable efficacy and safety results from the Phase 3 VALOR clinical trial, which showed over 70% efficacy in preventing Lyme disease in individuals aged five years and older. The companies are seeking to bring the first vaccine of its kind to Europe, addressing the over 100,000 annual cases of Lyme disease in the region.
Valneva reported its half-year 2026 financial results, with total product sales of €64.0 million, reiterating its full-year guidance. The company maintained a strong cash position of €121.5 million due to disciplined management and a recent offering, while also implementing a restructuring program. Valneva anticipates regulatory decisions for its Lyme disease vaccine candidate within the next year.
Valneva SE (VALN) is considered 7.4% overvalued according to GuruFocus's GF Value™ metric, trading at $5.54 per share against an intrinsic value of $5.16. The company reported a 32.5% year-over-year revenue decline in the first half of 2026 and is undergoing restructuring, including workforce reductions and asset sales, to mitigate cash burn. Valneva's GF Score™ of 53 reflects weak profitability and financial strength, despite moderate valuation and growth scores.
TD Cowen has upgraded Valneva (NASDAQ:VALN) to a "strong-buy" rating, although other analysts have mixed views, resulting in a consensus "Moderate Buy" rating with an average price target of $11.98. The company's shares opened at $5.59, significantly below its 52-week high, and it reported a quarterly loss of $0.42 per share on $35.77 million in revenue. Institutional investors hold 11.39% of Valneva, with recent new positions established by firms like JPMorgan Chase.